Suitable Effective Mode of Administration of Intravenous Ara-C in Acute Leukaemias

Naseeb Muhammad Irshadullah (1)
(1) Shaheed Tajuddin Ahmad Medical College, Gazipur , Bangladesh

Abstract

Abstract:


Ara-c is a commonly used drug in acute leukaemias. In different stages of treatment dose and mode of administration of this drug is variable. It is usually considered as a cell cycle specific drug, but except in ‘standard’ induction of remission therapy for acute myelogenous leukaemia it is not usually given by continuous infusion in other conditions. This article discusses about the different intravenous modes of administration of ara-c in AML induction chemotherapy, their outcomes, and urges for trials to find out a suitable mode of administration of this common drug.


Keywords: cytosine arabinoside, arabinocytosar, arabinosyl cytarabine, ara-c, cytarabine

Full text article

Generated from XML file

References

Mohan S, Talbott M, Hande KR. Principles and Pharmacology of Chemotherapy. In: Greer JP, Rodgers GM, Glader B, Arber DA, Means RT Jr., List AF, Appelbaum FR, Dispenzieri A. (eds.) Wintrobe’s Clinical Hematology. 14th ed. Philadelphia, PA: Wolters Kluwer; 2019.

Chu E, Laurie JH, Copur MS. Chemotherapeutic and Biologic Drugs. In: Chu E & DeVita VT. (eds.) Physicians’ Cancer Chemotherapy Drug Manual 2021. Massachusetts, MA: Jones & Bartlett Learning; 2022.

Gisselbrecht C, Lepage E, Lenoble M, Marty M, Boiron M. Therapy of acute leukemia in the adult. Role of anthracyclins. Pathol Biol (Paris). 1987 Jan;35(1):69-74.

Gmür J. Current status of therapy and prognosis in acute adult leukemia. Ther Umsch. 1996 Feb;53(2):111-6.

Rowe JM. What is the best induction regimen for acute myelogenous leukemia? Leukemia. 1998 Sep;12 Suppl 1:S16-9.

Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther. 2009;31 Pt 2:2349-70.

Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999 Sep 30;341(14):1051-62.

Islam MM. Outcome of Standard Induction Therapy with Daunorubicin and ARA-C (3+7) in AML (Except AML-M3) [FCPS dissertation]. Dhaka, Bangladesh: Bangladesh College of Physicians & Surgeons (BCPS); 2012.

Ahmed, M. Study of remission status in AML after 1st cycle of induction chemotherapy. [FCPS Dissertation]. Dhaka, Bangladesh: Bangladesh College of Physicians & Surgeons (BCPS); 2008.

Wei H, Zhou C, Lin D, Liu B, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Chen J, Zhang J, Jin J, Qiu S, Gu R, Wang Y, Mi Y, Wang J. Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia. Haematologica. 2020 Sep 28;106(5):1491-1495. doi: 10.3324/haematol.2020.267526. PMID: 33054134; PMCID: PMC8094090.

Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AK. Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults with Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10). Blood. 1997 April 1;89(7):2311-18.

Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin M-F, Duncombe A, Gibson B, Wheatley K. Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial. Journal of Clinical Oncology. 2009 Dec 28;28(4):586–95.

Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JAL, Hunter A, Goldstone AH, Wheatley K. Identi?cation of Patients With Acute Myeloblastic Leukaemia Who Bene?t From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial. Journal of Clinical Oncology. 2010 Dec 20;29(4):369–77.

MRC AML 17 protocol (2008). Working Parties On Leukaemia In Adults And Children Trial In Acute Myeloid Leukaemia Or High Risk Myelodysplastic Syndrome 17 (Version 8: October 2012). Trial Reference ISRCTN55675535. [Online] Cardiff: Cardiff University School of Medicine. Available at < https://trials.cardiff.ac.uk/aml/17/web/files/new5/AML%2017%20 Protocol%20V8.0%20October%202012.pdf > [Accessed on 05 December 2021].

Peters WG, Willemze R, Colly LP. Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-hodgkin’s lymphoma. European Journal of Cancer and Clinical Oncology. 1987 Apr;23(4):401–5.

Ferreri AJ, Reni M, Foppoli M, et al; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512-20.

Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147-8.

DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643-48.

Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548–53.

Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129–35. ) (Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol J Am Soc Clin Oncol. 2010;28:808–14.

Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig W, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck J, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H and Schrappe M. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008 May 1;111(9):4477-89.

1. Richards S, Burrett J, Hann I, Chessells J, Hill F, Bailey C, et al. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Leukemia. 1998 Jul 1;12(7):1031–6.

Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J, Kinsey S, Mitchell C, Eden OB. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia. 2000 Mar;14(3):356-63. doi: 10.1038/sj.leu.2401704. PMID: 10720126.

Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res. 1998;72:197-233.

Silagi S. Metabolism of 1-?-D-arabinofuranosylcytosine in L cells. Cancer Res. 1965 oct;25(9):1446-53.

Li Z, Guo J-R, Chen Q-Q, Wang C-Y, Zhang W-J, Yao M-C, Zhang W. Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells. Molecules. 2017; 22(3):499. https://doi.org/10.3390/molecules22030499

DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA, editors. Devita, Hellman, and Rosenberg’s cancer: Principles and practice of oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011 May 1. ISBN: 9781451105452.

Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. Cytosine Arabinoside with Daunorubicin or Adriamycin for Therapy of Acute Myelocytic Leukemia: A CALGB Study. Blood. 1982;60:454-62.

Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, Mclntyre OR, Schiffer C. A Comparative Study of Two Different Doses of Cytarabine for Acute Myeloid Leukemia: A Phase III Trial of Cancer and Leukemia Group B. Blood. 1991;78:2520-26.

Irshadullah NM, Kabir AL, Hossain MM, Wasim M, Chowdhury MSZ, Rumi MSIS, Begum M. Efficacy of ADE Protocol in Newly Diagnosis AML patients in Bangladesh. Dhaka Central International Medical College Journal; July 2020;7(2):22-27.

Pagnano KBB, Traina F, Takahashi T, Oliveira GB, Rossini MS, Lorand-Metze I, Vigorito AC, Miranda ECM, Souza CAD. Conventional chemotherapy for acute myeloid leukemia: A Brazilian experience. Sao Paulo Medical Journal. 2000 Nov 9;118(6):173-8.

Bishop JF. Adult acute myeloid leukaemia: update on treatment. Med J Aust. 1999 Jan;170(1):39-43.

Ashrafi F, Mehrzad V, Samimi M, Shahnazari R. Results of treatment of acute myeloid leukemia in central part of Iran. Advanced Biomedical Research. 2013;2(1):51.

Tsurumi H, Kanemura N, Hara T, Kasahara S, Yamada T, Sawada M, Oyama M, Moriwaki H. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: The efficacy of continuous drip infusion with low dose cytarabine and etoposide. Journal of Cancer Research and Clinical Oncology. 2007 Apr 24;133(8):547–53.

Irshadullah NM. Comparative Study Between Modified UK MRC AML 12 and Modified DA Protocols in BSMMU [MD thesis]. Dhaka, Bangladesh: Bangabandhu Sheikh Mujib Medical University (BSMMU); 2016.

Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, Aguayo A, López-Karpovitch X, Crespo-Solís E. Acute myeloid leukemia in adults: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán from 2003 to 2008. Rev Invest Clin. 2010 Mar-Apr;62(2):100-8.

Sackmann-Muriel F, Zubizarreta P, Felice MS, Chantada G, Cygler AM, Gallego M, Rossi J. Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. Leuk Res. 1996 Nov-Dec;20(11-12):973-81.

Lowenthal RM, Bradstock KF, Matthews JP, Bishop JF, Juneja S, Cobcroft R, Eliadis P, Enno A, Gill D, Herrmann RP, Manoharan A, Page FJ, Rooney KF, Rosenfeld D, Seldon M, Taylor KM, Wolf MM, Young GA. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG). Leuk Lymphoma. 1999 Aug;34(5-6):501-10.

Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, Gobbi M. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. J Exp Clin Cancer Res. 1999 Mar;18(1):55-60.

Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, Peaud P-Y, Martin C, Amadori S, Willemze R. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia. 1999 Jun;13(6):843–9.

Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, et al. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica. 2011;96:837–44.

Authors

Naseeb Muhammad Irshadullah
drnaseeb@gmail.com (Primary Contact)
Author Biography

Naseeb Muhammad Irshadullah, Shaheed Tajuddin Ahmad Medical College, Gazipur

Assistant Professor of Haematology, Shaheed Tajuddin Ahmad Medical College, Gazipur

1.
Irshadullah NM. Suitable Effective Mode of Administration of Intravenous Ara-C in Acute Leukaemias. Haematol J Bangladesh [Internet]. 2022 Jan. 31 [cited 2024 Mar. 29];6(1):30-7. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/86

Article Details

How to Cite

1.
Irshadullah NM. Suitable Effective Mode of Administration of Intravenous Ara-C in Acute Leukaemias. Haematol J Bangladesh [Internet]. 2022 Jan. 31 [cited 2024 Mar. 29];6(1):30-7. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/86